Product Description
Primaquine is used alone or with another medication to treat malaria (a serious infection that is spread by mosquitoes in certain parts of the world and can cause death) and to prevent the disease from coming back in people that are infected with malaria. Primaquine is in a class of medications called antimalarials. It works by killing the organisms that cause malaria. (Sourced from: https://medlineplus.gov/druginfo/meds/a607037.html)
Mechanisms of Action: Free Radical Inducer,DNA Converter
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Brazil | Canada | Cyprus | Czech | Ecuador | Greece | India | Indonesia | Japan | Korea | Malaysia | New Zealand | Pakistan | Peru | Philippines | Saudi Arabia | Slovenia | Thailand | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Cambodia, Ethiopia, Indonesia, Kenya, Pakistan
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Malaria, Vivax
Phase 2: Malaria, Falciparum
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CHMI-TransMod | P2 |
Suspended |
Malaria, Falciparum |
2025-12-01 |
|
| EFFORT | P3 |
Completed |
Malaria, Vivax |
2024-09-30 |
|
| CVIA 078 | P2 |
Completed |
Malaria, Falciparum |
2022-06-22 |